Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative but catalyst-rich biotech setup: Roche collaboration brought $700M upfront and up to $2.3B in potential payments, while NX-5948 Phase 1a/b data showed 92.9% ORR in second-line post-BTK CLL/SLL patients. Shares are up about 38% over the last 20 trading days, supported by a stronger biotech tape.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Support defended ⢠Resistance capped ⢠Consolidation phase Support Level: $22.70-$22.90 Resistance Level: $24.30-$24.70 Over the last month, NRIX has been mildly up but range-bound, with buyers defending $22.70-$22.90 support while repeated failure at $24.30-$24.70 resistance keeps the stock in consolidation.
Sentiment & News
Key News Insights: ⢠Roche Catalyst ⢠Earnings Miss ⢠HSR Clearance Nurix Therapeutics' stock has been propelled by its Roche partnership for bexobrutideg and regulatory progress, but recent earnings disappointment and mixed investor signals temper the outlook.
AI Summary
NRIX has shifted from a financing-stressed biotech to a better-capitalized, Roche-validated platform story, but the stock is still fundamentally a proof case whose upside now depends on bexobrutideg delivering clear late-stage differentiation in DAYBreak CLL-306, while the recent rerating leaves less room for disappointment.
Description
Nurix Therapeutics is a biopharmaceutical company that discovers and develops small-molecule treatments for oncology and immune disorders, with an emphasis on orally administered BTK degraders and CBLâB modulators. Its pipeline includes agents for relapsed or refractory Bâcell malignancies, therapies to support adoptive Tâcell approaches, and a cell therapy candidate in Phase 1 for gynecologic cancers. The company collaborates with Gilead and Sanofi, was incorporated in 2009, and is headquartered in San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 15 | Jul 22 | NRIX | Nurix Therapeutics, Inc. | Speculative but catalyst-rich biotech setup: Roche collaboration brought $700M upfront and up to $2.3B in potential payments, while NX-5948 Phase 1a/b data showed 92.9% ORR in second-line post-BTK CLL/SLL patients. Shares are up about 38% over the last 20 trading days, supported by a stronger biotech tape. | Closed | -1.1% |
| Jul 2 | Jul 9 | NRIX | Nurix Therapeutics, Inc. | Strong near-term catalyst and momentum setup: stock rose about 42% over 21 trading days, supported by Roche collaboration worth up to $2.3B with $700M upfront and positive NX-5948 CLL/SLL data including 92.9% ORR in a second-line group. | Closed | +3.0% |